Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

Malaria Journal

Volumn 16, Issue 1, 2017, Pages

  Plucinski, Mateusz M ^a   Dimbu, Pedro Rafael ^b   Macaia, Aleixo Panzo ^c   Ferreira, Carolina Miguel ^b   Samutondo, Claudete ^b   Quivinja, Joltim ^b   Afonso, Marília ^b   Kiniffo, Richard ^d   Mbounga, Eliane ^e   Kelley, Julia S ^a,f   Patel, Dhruviben S ^a   He, Yun ^a   Talundzic, Eldin ^a,f   Garrett, Denise O ^a   Halsey, Eric S ^a   Udhayakumar, Venkatachalam ^a   Ringwald, Pascal ^d   Fortes, Filomeno ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Ministry of Health   (Angola)

^c Universidade Agostinho Neto   (Angola)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e USAID   (Angola)

^f ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; AMODIAQUINE; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ANGOLA; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; BENGUELA; CHILD; DEMOCRATIC REPUBLIC CONGO; DRUG EFFICACY; FEMALE; GENE; HAPLOTYPE; HUMAN; K13 GENE; LUNDA SUL; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PFMDR1 GENE; PRESCHOOL CHILD; RECURRENT INFECTION; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT RESPONSE; DRUG COMBINATION; INFANT; RECURRENT DISEASE;

AMODIAQUINE; ANGOLA; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; QUINOLINES; RECURRENCE; TREATMENT FAILURE;

EID: 85011258189     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-017-1712-4     Document Type: Article

References (29)

1. World Health Organization. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2012.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67.
3. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357-65.
4. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50-5.
5. World Health Organization. World malaria report. Geneva: World Health Organization; 2014.
6. Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015;211:680-8.
7. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria (Review). Hoboken: Wiley Online Library; 2009.
8. Worldwide Antimalarial Resistance Network AL Dose Impact Study Group. The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infect Dis. 2015;15:692-702.
9. Adjuik MA, Allan R, Anvikar AR, Ashley EA, Ba MS, Barennes H, et al. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 2015;13:66.
10. Worldwide Antimalarial Resistance Network DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10:e1001564.
11. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:209-18.
12. Fançony C, Brito M, Gil JP. Plasmodium falciparum drug resistance in Angola. Malar J. 2016;15:74.
13. Van Hong N, Amambua-Ngwa A, Tuan NQ, Cuong DD, Giang NTH, Van Dung N, et al. Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam. Emerg Infect Dis. 2014;20:1207.
14. Ringwald P, Dondorp A. Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam [letter]. Emerg Infect Dis. 2015.
15. Van Hong N, Amambua-Ngwa A, Tuan NQ, Cuong DD, Giang NTH, Van Dung N, et al. Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam [letter]. Emerg Infect Dis. 2015;21:1265.
16. Kiaco K, Teixeira J, Machado M, do Rosário V, Lopes D. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola. Malar J. 2015;14:504.
17. Plucinski MM, Talundzic E, Morton L, Dimbu PR, Macaia AP, Fortes F, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, Angola. Antimicrob Agents Chemother. 2015;59:437-43.
18. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
19. Alam MT, Vinayak S, Congpuong K, Wongsrichanalai C, Satimai W, Slutsker L, et al. Tracking origins and spread of sulfadoxine-resistant Plasmodium falciparum dhps alleles in Thailand. Antimicrob Agents Chemother. 2011;55:155-64.
20. Alam MT, de Souza DK, Vinayak S, Griffing SM, Poe AC, Duah NO, et al. Selective sweeps and genetic lineages of Plasmodium falciparum drug-resistant alleles in Ghana. J Infect Dis. 2011;203:220-7.
21. Talundzic E, Chenet SM, Goldman IF, Patel DS, Nelson JA, Plucinski MM, et al. Genetic analysis and species specific amplification of the artemisinin resistance-associated Kelch propeller domain in P. falciparum and P. vivax. PLoS ONE. 2015;10:e0136099.
22. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J. 2013;12:103.
23. Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust algorithm for systematic classification of malaria late treatment failures as recrudescence or reinfection using microsatellite genotyping. Antimicrob Agents Chemother. 2015;59:6096-100.
24. Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS ONE. 2014;9:e105690.
25. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS ONE. 2009;4:e6358.
26. Ezzet F, Van Vugt M, Nosten F, Looareesuwan S, White N. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697-704.
27. Okell LC, Cairns M, Griffin JT, Ferguson NM, Tarning J, Jagoe G, et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Comm. 2014;5:5606.
28. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis. 2013;207:842-7.
29. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health. 2007;12:736-42.